MX2016004285A - Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. - Google Patents

Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.

Info

Publication number
MX2016004285A
MX2016004285A MX2016004285A MX2016004285A MX2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A
Authority
MX
Mexico
Prior art keywords
gamma
interferon
composition
drug
loaded
Prior art date
Application number
MX2016004285A
Other languages
English (en)
Other versions
MX384311B (es
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of MX2016004285A publication Critical patent/MX2016004285A/es
Publication of MX384311B publication Critical patent/MX384311B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan las composiciones y métodos para tratamientos de cáncer, la metodología implica, por ejemplo, administrar a un paciente con cáncer una primera composición que comprende una pluralidad de minicélulas intactas derivadas de bacterias o células bacterianas eliminadas intactas, cada una de las cuales abarca un agente anti-neoplásico y porta un ligando inespecífico en la superficie, el ligando tiene especificidad para un componente de la célula de mamífero y una segunda composición que comprende interferón-gamma (IFN-gamma) o un agente que incrementa la expresión de IFN-gamma en el sujeto; las composiciones incluyen la primera composición y la segunda composición como se describe, opcionalmente con agentes anti-neoplásicos adicionales.
MX2016004285A 2013-10-04 2014-10-03 Combinación con minicélulas dirigidas por ligando, biespecíficas, cargadas con fármacos e interferón-gamma para usarse en el tratamiento de tumores. MX384311B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887258P 2013-10-04 2013-10-04
PCT/IB2014/002824 WO2015049589A1 (en) 2013-10-04 2014-10-03 Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Publications (2)

Publication Number Publication Date
MX2016004285A true MX2016004285A (es) 2016-07-08
MX384311B MX384311B (es) 2025-03-14

Family

ID=52777107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004285A MX384311B (es) 2013-10-04 2014-10-03 Combinación con minicélulas dirigidas por ligando, biespecíficas, cargadas con fármacos e interferón-gamma para usarse en el tratamiento de tumores.

Country Status (15)

Country Link
US (2) US9731011B2 (es)
EP (1) EP3052122B1 (es)
JP (1) JP6538031B2 (es)
KR (1) KR102433719B1 (es)
CN (1) CN105658233B (es)
AP (1) AP2016009153A0 (es)
AU (1) AU2014330895B2 (es)
CA (1) CA2926161C (es)
EA (1) EA032740B1 (es)
IL (1) IL244851B (es)
MX (1) MX384311B (es)
NZ (1) NZ718148A (es)
SG (1) SG11201602429QA (es)
TW (1) TWI737576B (es)
WO (1) WO2015049589A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6538031B2 (ja) * 2013-10-04 2019-07-03 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
US11485976B2 (en) * 2016-10-06 2022-11-01 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
SG11202100507PA (en) * 2018-07-23 2021-02-25 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CN113507936A (zh) * 2019-01-04 2021-10-15 安吉尼科分子传输公司 用于治疗赘生性疾病的包封的糖脂抗原
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP4126031A4 (en) * 2020-03-24 2024-03-27 EnGeneIC Molecular Delivery Pty Ltd. COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRUS INFECTIONS, INCLUDING CORONAVIRUS INFECTIONS, AND METHODS OF USE THEREOF
US12357687B2 (en) 2020-03-24 2025-07-15 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
US12551550B2 (en) 2021-07-22 2026-02-17 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2315067B (en) 1996-07-11 2000-02-16 Pharmacia Spa Morpholinyl anthracycline derivatives
KR20020008186A (ko) 1999-05-11 2002-01-29 다우 케네드 제이. 에리트로포이에틴 투여의 약동학 및 약역학 모델링
IL149267A0 (en) * 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2463631C (en) 2001-10-15 2012-07-03 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
WO2004074314A2 (en) * 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
EP1694361B1 (en) * 2003-12-09 2011-03-16 EnGeneIC Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
AU2005215254B2 (en) * 2004-02-02 2009-11-12 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
CA2803995C (en) 2004-08-26 2014-06-10 Engeneic Molecular Delivery Pty Ltd. Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
DK2386640T3 (en) * 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
US7739708B2 (en) * 2005-07-29 2010-06-15 Yahoo! Inc. System and method for revenue based advertisement placement
PL2712618T3 (pl) 2006-06-23 2017-07-31 Engeneic Molecular Delivery Pty Ltd. Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne
CA2682704C (en) 2007-03-30 2014-07-08 Engeneic Molecular Delivery Pty. Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
BR112013013127B1 (pt) 2010-12-02 2021-06-22 Nerviano Medical Sciences S.R.L. Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos
RU2664698C2 (ru) * 2011-12-13 2018-08-21 Энджинеик Молекьюлар Деливери Пти Лтд Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга
EP2903653B1 (en) * 2012-10-02 2020-07-08 Vaxiion Therapeutics, LLC Immunomodulatory minicells and methods of use
JP6538031B2 (ja) * 2013-10-04 2019-07-03 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療

Also Published As

Publication number Publication date
CN105658233B (zh) 2020-09-04
US9731011B2 (en) 2017-08-15
CN105658233A (zh) 2016-06-08
JP2016532639A (ja) 2016-10-20
KR102433719B1 (ko) 2022-08-17
AP2016009153A0 (en) 2016-04-30
TWI737576B (zh) 2021-09-01
BR112016007100A2 (pt) 2017-08-01
JP6538031B2 (ja) 2019-07-03
KR20160058885A (ko) 2016-05-25
WO2015049589A1 (en) 2015-04-09
CA2926161C (en) 2023-03-14
EP3052122A1 (en) 2016-08-10
US20150098897A1 (en) 2015-04-09
AU2014330895B2 (en) 2019-08-15
EA032740B1 (ru) 2019-07-31
TW201601748A (zh) 2016-01-16
AU2014330895A1 (en) 2016-04-14
IL244851B (en) 2020-04-30
US10500277B2 (en) 2019-12-10
HK1223281A1 (en) 2017-07-28
EP3052122A4 (en) 2017-05-17
IL244851A0 (en) 2016-05-31
CA2926161A1 (en) 2015-04-09
US20170326235A1 (en) 2017-11-16
EP3052122B1 (en) 2024-09-25
SG11201602429QA (en) 2016-04-28
NZ718148A (en) 2022-02-25
MX384311B (es) 2025-03-14
EA201690680A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
MX2015000438A (es) Manejo de toxicidad para actividad antitumoral de cars.
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
MX2015003643A (es) Metodo para tratar el cancer.
CR20120528A (es) Métodos para tratar el cáncer
MX375838B (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2019014800A (es) Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso.
AR094026A1 (es) Metodo para activar la celula t helper
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2018002640A (es) Seleccion de pacientes para la terapia de combinacion.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
CY1124082T1 (el) Μεθοδοι θεραπειας με χρηση κινητοποιητων βλαστικων κυτταρων και ανοσοκατασταλτικων παραγοντων